Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

AIM: To compare the effects of combining liraglutide (0.6, 1.2 or 1.8 mg/day) or rosiglitazone 4 mg/day (all n ≥ 228) or placebo (n = 114) with glimepiride (2–4 mg/day) on glycaemic control, body weight and safety in Type 2 diabetes. METHODS: In total, 1041 adults (mean ± sd), age 56 ± 10 years, wei...

Descripción completa

Detalles Bibliográficos
Autores principales: Marre, M, Shaw, J, Brändle, M, Bebakar, W M W, Kamaruddin, N A, Strand, J, Zdravkovic, M, Le Thi, T D, Colagiuri, S
Formato: Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2009
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2871176/
https://www.ncbi.nlm.nih.gov/pubmed/19317822
http://dx.doi.org/10.1111/j.1464-5491.2009.02666.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2871176/
https://www.ncbi.nlm.nih.gov/pubmed/19317822
http://dx.doi.org/10.1111/j.1464-5491.2009.02666.x

Ejemplares similares